D 201
Alternative Names: D-201Latest Information Update: 27 Aug 2024
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neuroendocrine tumours; Small cell lung cancer
Most Recent Events
- 31 Jul 2024 Preclinical trials in Neuroendocrine tumours in USA (Parenteral), prior to July 2024 (TCR Cure Biopharma, July 2024)
- 31 Jul 2024 Preclinical trials in Small cell lung cancer in USA (Parenteral), prior to July 2024 (TCR Cure Biopharma, July 2024)